Rhythm Pharmaceuticals (MEX:RYTM) Quality Rank


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
55 GF Score
Price MXN1,866.76
GF Value MXN1,817.22
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Rhythm Pharmaceuticals Quality Rank Related Terms

MEX:RYTM
55GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,866.76 is trading 2.7% above its estimated GF Value™ of MXN1,817.22.

Key valuation signals for MEX:RYTM:

  • Quality Rank:
  • GF Value™: MXN1,817.22 vs. price of MXN1,866.76 (2.7% above fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
55GF Score

Get the complete analysis for MEX:RYTM

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,817.22
GF Value